Inhibition of glucose utilization for acetylcholine synthesis by cerebrospinal fluid.
D000109:Acetylcholine / Q000096:biosynthesis*; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002245:Carbon Dioxide / Q000378:metabolism; D002415:Cats; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000134:cerebrospinal fluid*; D005947:Glucose / Q000378:metabolism*; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000378:metabolism; D006593:Hexokinase / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D010732:Phosphofructokinase-1 / Q000378:metabolism; D010830:Physostigmine / Q000494:pharmacology; D011770:Pyruvate Kinase / Q000378:metabolism; D011773:Pyruvates / Q000378:metabolism; D051381:Rats
D004791:Enzyme Inhibitors; D011773:Pyruvates; D002245:Carbon Dioxide; D010830:Physostigmine; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D002795:Choline O-Acetyltransferase; D006593:Hexokinase; D010732:Phosphofructokinase-1; D011770:Pyruvate Kinase; D005947:Glucose; D000109:Acetylcholine